Published 20 hours ago • loading... • Updated 20 hours ago

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

On Saturday, Eli Lilly and Company announced that Taltz plus Zepbound achieved superior efficacy at 36 weeks for adults with active psoriatic arthritis and obesity, compared to Taltz monotherapy in the TOGETHER-PsA Phase 3b trial.
Approximately 65% of adults with psoriatic arthritis also have obesity or overweight with at least one weight-related comorbidity, creating a difficult disease burden often associated with poorer clinical outcomes and complicating treatment approaches.
The combination achieved 31.7% primary endpoint response versus 0.8% for Taltz alone, while 84.5% of patients receiving the combination achieved at least 10% weight reduction at Week 36.
Participants reported meaningful improvements in daily life, with FACIT-Fatigue scores increasing by 8.6 and HAQ-DI disability index scores decreasing by 0.5, alongside reductions in systemic inflammation.
Philip Mease, M.D., Director of Rheumatology Research at Swedish Medical Center, said the evidence "supports a potential transformation in how we approach treatment" for patients managing both conditions simultaneously.

Insights by Ground AI

36 Articles

The Berkshire Eagle

+35 Reposted by 35 other sources

Center

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study

20 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year